Searched over 200M research papers
10 papers analyzed
These studies suggest that angiotensin II affects cardiovascular and renal function, influences blood flow and insulin sensitivity, and has both therapeutic and adverse effects depending on the context.
20 papers analyzed
Angiotensin II (Ang II) is a critical hormone in the renin-angiotensin system, playing a significant role in regulating blood pressure and fluid balance. It is also implicated in various cardiovascular and renal diseases, making it a focal point for therapeutic interventions.
Angiotensin II is a key player in the progression of myocardial hypertrophy to heart failure. It exerts its effects through different angiotensin receptors, which are variably expressed in cardiomyocytes depending on the heart's condition (neonatal, adult, or failing). The hormone's intracellular actions are influenced by nitric oxide (NO)/cGMP-dependent pathways and are mediated by autocrine factors like transforming growth factor (TGF)-beta1 and interleukin (IL)-6. Additionally, Ang II interacts with other systemic hormones such as aldosterone and parathyroid hormone, which can modify its primary effects on cardiomyocytes.
Clinical studies have shown that intravenous administration of Ang II is generally safe, with adverse events being infrequent. However, serious side effects such as exacerbation of left ventricular failure and bronchoconstriction have been reported. In patients with congestive heart failure, Ang II can worsen the condition, and in rare cases, it has been fatal. Despite these risks, the overall safety profile supports its use under controlled conditions.
In experimental models of hyperdynamic sepsis, Ang II has been shown to restore arterial pressure and significantly increase urine output and creatinine clearance, despite reducing renal blood flow. This suggests that Ang II can be beneficial in managing sepsis-induced hypotension while improving renal function.
Blocking Ang II receptors with antagonists like irbesartan leads to a compensatory increase in plasma renin activity and Ang II levels, along with a decrease in plasma aldosterone levels. This blockade results in increased sodium and chloride excretion without significantly altering renal blood flow or glomerular filtration rate. These findings highlight the potential of Ang II receptor blockers in managing hypertension and related renal issues.
Angiotensin II has been found to enhance insulin sensitivity, particularly by increasing skeletal muscle blood flow. However, this effect is mediated through subtype 1 receptors, which are typically associated with vasoconstriction. Interestingly, acute infusion of Ang II does not significantly affect whole-body insulin sensitivity, indicating that its impact may be more localized.
In a pig model of cardiopulmonary resuscitation, Ang II administration improved myocardial blood flow and acid-base status, leading to better short-term resuscitation outcomes. This suggests that Ang II can enhance myocardial perfusion during critical conditions like CPR.
Angiotensin II exerts a positive inotropic effect on human cardiac muscle, with varying responsiveness depending on the muscle's condition (normal vs. failing). This effect is not mediated by cyclic AMP, indicating a unique pathway for Ang II's action on cardiac muscle.
Angiotensin II decreases local blood flow in adipose and skeletal muscle tissues and inhibits lipolysis. These effects are consistent across normal-weight and obese subjects, suggesting a broad impact of Ang II on metabolic processes.
At the molecular level, Ang II influences various cellular processes, including cell growth, gene expression, and activation of intracellular signaling pathways. These actions contribute to conditions like cardiac hypertrophy, heart failure, vascular thickening, atherosclerosis, and glomerulosclerosis.
Angiotensin II plays a multifaceted role in cardiovascular and renal health, influencing everything from blood pressure regulation to myocardial function and metabolic processes. While it offers therapeutic potential, particularly in conditions like sepsis and heart failure, its administration must be carefully managed due to potential adverse effects. Understanding the complex interactions and mechanisms of Ang II can help refine therapeutic strategies and improve patient outcomes.
Most relevant research papers on this topic